Comparison between Avience Biomedicals IPO and Grand Continent Hotels IPO.
Avience Biomedicals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Grand Continent Hotels IPO is a SME Bookbuilding proposed to list at NSE SME.
| Avience Biomedicals IPO | Grand Continent Hotels IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Fintellectual Corporate Advisors Pvt.Ltd. | Indorient Financial Services Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Asnani Stock Broker Pvt.Ltd. | Alacrity Securities Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Avience Biomedicals IPO is up to ₹0.00 Cr whereas the issue size of the Grand Continent Hotels IPO is up to ₹70.73 Cr. The final issue price of Avience Biomedicals IPO is and of Grand Continent Hotels IPO is ₹113.00 per share.
| Avience Biomedicals IPO | Grand Continent Hotels IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹107.00 per share | |
| Issue Price (Upper) | ₹113.00 per share | |
| Issue Price (Final) | ₹113.00 per share | |
| Discount (Retail) | ₹0.00 per share | |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 15,27,600 shares | 59,30,400 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹67.01 Cr |
| OFS Issue Size | 0 shares | 3,28,800 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹3.72 Cr |
| Issue Size Total | 15,27,600 shares | 62,59,200 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹70.73 Cr |
Avience Biomedicals IPO opens on , while Grand Continent Hotels IPO opens on Mar 20, 2025. The closing date of Avience Biomedicals IPO and Grand Continent Hotels IPO is , and Mar 24, 2025, respectively.
| Avience Biomedicals IPO | Grand Continent Hotels IPO | |
|---|---|---|
| Anchor Bid Date | Mar 19, 2025 | |
| Issue Open | Mar 20, 2025 | |
| Issue Close | Mar 24, 2025 | |
| Basis Of Allotment (Tentative) | Mar 25, 2025 | |
| Initiation of Refunds (Tentative) | Mar 26, 2025 | |
| Credit of Share (Tentative) | Mar 26, 2025 | |
| Listing date (Tentative) | Mar 27, 2025 | |
| Anchor Lockin End date 1 | Apr 24, 2025 | |
| Anchor Lockin End date 2 | Jun 23, 2025 |
Avience Biomedicals IPO P/E ratio is , as compared to Grand Continent Hotels IPO P/E ratio of 51.24.
| Avience Biomedicals IPO | Grand Continent Hotels IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Avience Biomedicals Ltd.'s revenue increased by 89% and profit after tax (PAT) rose by 239% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.85 | 75.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 66.37 | 54.85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 51.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹281.59 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.14 | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 24.84 | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.97 | 1.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 50.14 | 26.67 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Avience Biomedicals IPO Retail Individual Investors (RII) are offered 0 shares while in Grand Continent Hotels IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Avience Biomedicals IPO and 12,49,200 shares in Grand Continent Hotels IPO.
| Avience Biomedicals IPO | Grand Continent Hotels IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,73,200 shares | |
| Market Maker Reservation | 80,400 shares | 3,30,000 shares |
| QIB | 0 shares | 12,49,200 shares |
| NII | 0 shares | 9,37,200 shares |
| RII | 0 shares | 21,87,600 shares |
| Employee | 0 shares | 12,000 shares |
| Others | ||
| Total | 0 shares | 62,59,200 shares |
Avience Biomedicals IPO subscribed in total, whereas Grand Continent Hotels IPO subscribed 1.79x.
| Avience Biomedicals IPO | Grand Continent Hotels IPO | |
|---|---|---|
| QIB (times) | 2.93x | |
| NII (times) | 1.39x | |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 1.32x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.79x |
